ALLO
Allogene Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$633.82M
P/E Ratio
—
EPS
$-0.87
Beta
0.54
52W High
$2.80
52W Low
$0.86
50-Day MA
$2.16
200-Day MA
$1.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-150.15M |
| EBITDA | $-194.57M |
| Operating Margin | 0.00% |
| Return on Equity | -53.40% |
| Return on Assets | -26.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.27 |
| Price-to-Book | 2.07 |
| Price-to-Sales (TTM) | 7784.36 |
| EV/Revenue | 3859.62 |
| EV/EBITDA | -1.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $243.78M |
| Float | $187.40M |
| % Insiders | 15.32% |
| % Institutions | 61.21% |
Analyst Ratings
Consensus ($7.47 target)
3
Strong Buy10
Buy1
Hold1
Strong SellData last updated: 4/7/2026